Table 1. Summary of selected cases included in this study.
| Duration PMI | Pathological diagnosis | IHQ: | βA in OB | IHQ: TAU in OB | |||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | age | sex | (years) | (hours) | NIA-AA criteria | MP | DP | Tangles | neurites |
| Control | |||||||||
| C1 | 72 | M | 9 | Thal 1 Cerad 1 no tau deposit | − | − | − | + | |
| C2 | 103 | M | 3 | No protein deposit+vascular disease | − | − | − | + | |
| C3 | 81 | F | 3.3 | PART (Braak I)+vascular disase | − | − | − | + | |
| C4 | 61 | M | 8 | PART (Braak I) | − | − | + | − | |
| Low AD | |||||||||
| I1 | 88 | M | 1 | 3.45 | AD (A2B1C2) | ++ | + | ++ | ++ |
| I2 | 85 | F | 8 | 2 | AD (A2B1C1) | − | − | + | + |
| I3 | 80 | M | 5 | 3 | AD (A2B1C1) | ++ | ++ | ++ | +++ |
| I4 | 75 | F | n.d | 6 | AD (A1B1C1) | − | − | + | + |
| I5 | 72 | F | n.d | 4 | AD (A1B1C1) | − | − | + | + |
| intermediate AD | |||||||||
| M1 | 85 | M | 12 | 3.3 | AD (A2B2C2) | − | + | +++ | +++ |
| M2 | 97 | F | 9 | n.d | AD (A2B2C2) | n.d | n.d | n.d | n.d |
| M3 | 77 | M | 17 | 1.5 | AD (A2B2C1) | − | − | ++ | ++ |
| M4 | 86 | F | 9 | 3 | AD (A2B2C2) | − | + | ++ | ++ |
| High AD | |||||||||
| A1 | 77 | F | 16 | 4 | AD (A2B3C3) | + | +++ | +++ | +++ |
| A2 | 70 | M | 4 | 2.5 | AD (A3B3C3) | ++ | +++ | ++ | +++ |
| A3 | 89 | M | 13 | 3 | AD (A2B3C3) | + | +++ | +++ | +++ |
| A4 | 86 | M | 8 | 2.5 | AD (A3B3C3) | + | − | + | ++ |
| A5 | 93 | M | 3 | 2.4 | AD (A3B3C3) | + | +++ | +++ | +++ |
The neuropathological assessment was performed according to Thal phases, adapted CERAD score, NIA-AA guidelines and PART criteria. Aβ immunopositivity was scored on a 4-tiered scale as: (−) negative, (+) 1–2isolated Aβ depositions, (++) 3–4Aβ depositions, and (+++) >4 Aβ depositions. Graduation of phospho-TAU deposit: (−) negative +: low; ++: intermediate; +++ high. PMI: post-mortem interval; n.d: not determined; MP: Mature plaques; DP: Diffuse plaques.